Yangzijiang Pharmaceutical continues to make efforts in the field of cardiovascular disease domestic contrast agent "Xinsu" will be successfully held

Author: Tang Yumin from China Food and Drug Network

On July 18, Yangzijiang Pharmaceutical Group's contrast agent "Xinsu" (perfluoropropane human blood albumin microspheres for injection) was launched in Taizhou, Jiangsu Province. Centering on the theme of "Set sail from the heart", the event adopted the mode of "online + offline" and set up a number of sub-venues in Tianjin, Hefei and other places, and simultaneously broadcast in the ultrasonic College. Academician Zhang Yun of Shandong University Qilu Hospital, Professor Xu Di of Jiangsu Provincial People's Hospital, and more than a dozen industry experts and professors from all over the country attended to talk about new drugs and Taoism.

At the meeting, online and offline experts linked up and joined hands with senior leaders such as Xu Jingren, chairman of Yangzijiang Pharmaceutical Group, to jointly help "Xinsu" successfully list. The conference also set up a cardiac CEUS forum, and the participating experts had in-depth discussions on the current situation of domestic CEUS development and the future policy trends of the industry. The meeting invited the original research team of "Xinsu" to share and exchange information, describing the research and development process from the project to the approval of new drugs and clinical use, which attracted more than 38,800 people from all over the country to watch the live broadcast.

It is understood that CEUS is an enhanced imaging technology that uses strong echo scattering of contrast media to improve the contrast resolution of ultrasound images, improve the sensitivity and specificity of detection, and has been widely used in left ventricular structure and function assessment, intracardial abnormalities, severe and emergency monitoring.

Under the leadership of the original research team such as Professor Liu Yili and Professor Chen Zhiliang in Nanfang Hospital, the domestic ultrasound contrast agent "Xinsu" has been researched and developed for nearly 20 years, and after the second and third phase clinical trials in many authoritative hospitals, it has been introduced and marketed by Yangzijiang Pharmaceutical. It is used for patients with insufficient clarity in conventional echocardiography development to enhance the imaging effect. Increase the rate of lesion identification and accuracy of lesion characterization, as well as the identification of left ventricle intima boundary.

Xu Jingren, chairman of Yangzijiang Pharmaceutical Group, said that national enterprises should have a mission and responsibility, and only pay attention to the research and development and introduction of innovative drugs and enhance the innovation ability of medical science and technology can better protect the good life of the people.

Over the years, Yangzijiang Pharmaceutical has continued to increase the development of new products in the field of cardiovascular disease, and on the basis of the original cardiovascular product layout, it has successively launched Kosell Speedline (PTCA balloon) and Youchang. New products such as fonda liver decane sodium. The newly listed ultrasound contrast agent "Xinsu" (perfluoropropane human blood albumin microspheres for injection) will provide more drug choices for the majority of cardiology and ultrasound clinicians.